Translate
Arrowhead Pharmaceuticals, Inc.
About
75.42USD-1.72 -2.23%
Closed • Updated at 13:54 GMT+00:00Market Cap$10.62B
Volume49.3K
Beta1.75
RSI53.38
Gross Margin95.92%
Arrowhead Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
May 5 2026
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 4 2026
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
May 1 2026
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Apr 24 2026
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe